Creatine HCl Supplementation in Sarcopenia: A Randomized Controlled Study

ConditionSarcopenia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age60+
SponsorCenter for Health Sciences, Serbia

About this trial

The CONCRET-SARCOPA trial is a 12-week, double-blind, randomized controlled study designed to evaluate the efficacy of creatine HCl supplementation in older adults with sarcopenia. The trial investigates whether daily creatine HCl improves body composition, enhances functional muscle and cognitive performance, and favorably alters key blood biomarkers associated with muscle health and metabolic status. Additionally, the study assesses changes in tissue creatine levels using non-invasive and biochemical methods to clarify mechanistic responses to supplementation. Findings from this trial will provide critical evidence on the therapeutic potential of creatine HCl as a targeted nutritional strategy for managing sarcopenia in the geriatric population.

Eligibility criteria

Qualifiers

Age > 60 years

Low muscle strength by handgrip (SDOC criteria for sarcopenia): < 35.5 kg in men and < 20 kg in women

Sign free and informed consent

Demonstrate interest, conditions and availability to participate

Disqualifiers

Patients undergoing interventional treatment for sarcopenia

Physical amputation

Cognitive impairment (MSSE < 25)

Unwillingness to return for follow-up analysis

Trial design

Treatments tested in this trial

  • Experimental 1
  • Experimental 2

Treatment groups

30 Participants
are divided into 2 treatment groups